IGF-1 LR3

IGF-1 LR3 is the long-acting version, with a half-life of over 20 hours, making it ideal for systemic, body-wide muscle growth. IGF-1 DES is a shorter-acting, more potent variant that is often used for localized site enhancement right before a workout, as it binds to receptors more readily but is cleared from the body much faster.

IGF-1 has an insulin-like structure and can bind to insulin receptors, though with less affinity than insulin itself. This binding causes cells to take up glucose from the blood, which can lead to a rapid drop in blood sugar levels. This is why it's critical to consume carbohydrates around the time of administration, especially post-workout.

While its primary role is anabolic (muscle building), IGF-1 LR3 does promote lipolysis, or the breakdown of fat for energy. It helps shuttle nutrients preferentially towards muscle cells instead of fat cells. However, peptides like Semaglutide or Tesamorelin are far more effective if fat loss is the primary goal.

Both methods are effective. Because LR3 is systemic and long-acting, the specific injection location is less critical than with other peptides. Many users prefer intramuscular injection in the muscle group they just trained, under the theory it enhances local receptor activation, but subcutaneous injection works perfectly well for achieving systemic effects.

Due to its potency and the potential for receptor downregulation, IGF-1 LR3 cycles are typically kept short. Most research protocols run for 4 to 6 weeks, followed by an equally long break. Running it for longer periods often yields diminishing returns and may increase the risk of side effects.